. 2019 Nov 20;134(21):1796–1801. doi: 10.1182/blood.2019001321

Table 2.

Relevant phase 3 clinical trials in CLL

Trial	Regimens compared	ORR, %	PFS	OS	Results
CLL8³¹	FC	80	Median, 32.9 mo	Median, 86 mo	FCR is superior to FC in terms of PFS
	FCR	90	Median, 56.8 mo	Median, not reached	FCR is superior to FC in terms of PFS
CLL10²¹	FCR	95	Median, 55.2 mo	3-y, 91%	BR is inferior to FCR in terms of PFS
	BR	96	Median, 41.7 mo	3-y, 92%
CLL11²⁰	Ch	65.7	Median, 11.1 mo	NR	ChO is superior to Ch and ChR in terms of PFS and OS
	ChR	31.4	Median, 15.4 mo	NR
	ChO	77.3	Median, 29.2 mo	NR
RESONATE 2²⁶	Ch	35	24-mo, 34%	24-mo, 84%	Ibrutinib is superior to Ch in terms of PFS and OS
	Ibrutinib	92	24-mo, 89%	24-mo, 95%
E1912³⁴	IR	96	3-y, 89%	3-y, 99%	IR is superior to FCR in terms of PFS and OS
	FCR	81	3-y, 73%	3-y, 92%
A041202²⁸	BR	81	2-y, 74%	2-y, 95%	Ibrutinib and IR are superior to BR in terms of PFS, IR is no more effective than ibrutinib in terms of PFS
	Ibrutinib	93	2-y, 87%	2-y, 90%
	IR	94	2-y, 88%	2-y, 94%
iLLUMINATE³⁰	ChO	73	30-mo, 31%	30-mo, 85%	IO is superior to ChO in terms of PFS
	IO	88	30-mo, 79%	30-mo, 86%
CLL14³⁵	ChO	71.3%	2-y, 64.1%	2-y, 93.3%	VO is superior to ChO in terms of PFS
	VO	84.7%	2-y, 88.2%	2-y, 91.8%

BR, bendamustine/rituximab; Ch, chlorambucil; ChO, chlorambucil/obinutuzumab; ChR, chlorambucil/rituximab; FC, fludarabine/cyclophosphamide; FCR, fludarabine/cyclophosphamide/rituximab; IO, ibrutinib/obinutuzumab; IR, ibrutinib/rituximab; iwCLL, International Working Group on CLL; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.